EGFR and neoplasm: In this context, aberrant ErbB signaling can also alter the tumor cells’ transcriptome, including the expression of tumor-associated antigens (TAA) and tumor-specific antigens (TSA), therefore influencing both the pool of processing peptides available for antigen presentation and the MHC repertoire present at the surface of tumor cells (152).